1
|
The efficacy of a topical formulation of selamectin plus sarolaner in preventing the development of a macrocyclic lactone-resistant strain of Dirofilaria immitis in cats. Vet Parasitol 2020; 282:109122. [PMID: 32460111 DOI: 10.1016/j.vetpar.2020.109122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 04/17/2020] [Accepted: 04/21/2020] [Indexed: 11/22/2022]
Abstract
Revolution®/Stronghold® Plus, a topical endectocide incorporating 6 mg/kg selamectin plus 1 mg/kg sarolaner, is approved for use in cats to prevent heartworm disease. The efficacy of selamectin has not previously been evaluated against any macrocyclic lactone (ML)-resistant heartworm strains in cats for prevention of heartworm disease. In this study, an experimental combination formulation of selamectin (6 mg/kg) plus sarolaner (2 mg/kg) was assessed for preventing the development of a ML-resistant strain of Dirofilaria immitis in cats. Forty purpose-bred domestic shorted-haired cats (20 males; 20 females) from 7-9 months of age and negative for heartworm antigen prior to study inclusion were used. On Day -30, cats were inoculated with 100 D. immitis L3 (ZoeMO strain) subcutaneously in the inguinal area. Cats were randomly allocated to one of the following four treatments with associated dosing regimens: T01 (vehicle-treated control on Days 0, 28, and 56), T02 (single dose of selamectin plus sarolaner combination on Day 0 only), T03 (selamectin plus sarolaner combination on Days 0, 28, and 56) or T04 (single dose of selamectin on Day 0 only). All treatments were administered topically in an isopropyl alcohol-based formulation. Selamectin was administered at 6 mg/kg in both standalone and combination formulations. Sarolaner was administered at 2 mg/kg. Cats were necropsied on Day ∼145 (∼175 days post infection) and adult worms were counted. Nine of ten cats in the control group (T01) were infected with adult worms (range, 1-23; geometric mean, 3.5). In contrast, all cats in T03 had zero heartworms. Only two cats in T02 (0-3; 0.2) and a single cat in the T04 (0-1; 0.1) had heartworms. Compared to T01 (control cats), all treated cats had significantly (p < 0.0001) reduced worm burdens, with treatment efficacies of 100% (T03), 93.5% (T02) and 98% (T04). A topical combination of selamectin (6 mg/kg) plus sarolaner (2 mg/kg) was 100% efficacious in preventing the development of an ML-resistant strain of D. immitis (ZoeMO) in cats when administered as three consecutive monthly treatments. A single dose was highly (93.5%) but incompletely effective.
Collapse
|
2
|
Vatta AF, Young DR, King VL, Myers MR. Comparative efficacy of topical treatments with Revolution ® Plus (selamectin and sarolaner) and Bravecto ® for Cats (fluralaner) against Ixodes scapularis ticks on cats. Vet Parasitol 2019; 270 Suppl 1:S58-S63. [PMID: 31182302 DOI: 10.1016/j.vetpar.2019.05.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 05/23/2019] [Accepted: 05/24/2019] [Indexed: 10/26/2022]
Abstract
The efficacy of three consecutive monthly treatments with a novel topical product (Revolution® Plus/Stronghold® Plus, Zoetis) containing selamectin in combination with the isoxazoline, sarolaner, was compared with that of another topical isoxazoline, fluralaner [Bravecto® (fluralaner topical solution) for Cats, Merck] against Ixodes scapularis ticks on cats. Twenty-four cats were ranked by pre-treatment tick counts to form groups of three and were randomly allocated to be treated with placebo, the minimum label dosage of Revolution® Plus (6 mg/kg selamectin plus 1 mg/kg sarolaner) or the minimum label dosage of Bravecto® for Cats (40 mg/kg fluralaner) within the groups. On Days 0, 30, and 60, each cat in the placebo and Revolution® Plus-treated groups was treated topically, whereas cats in the Bravecto® for Cats-treated group were treated topically once on Day 0 with fluralaner and, subsequently, these animals were treated with the placebo on Days 30 and 60 to maintain masking. Doses were calculated based on weight to provide the minimum label dosage for each product; the calculated volume of product to be administered was rounded off to the nearest 0.1 mL. The selamectin plus sarolaner-treated cats received effective dosages of 5.29-7.12 mg/kg selamectin and 0.88-1.19 mg/kg sarolaner, while the fluralaner cats received dosages of 35.21-43.16 mg/kg fluralaner. Cats were infested with approximately 50 unfed viable adult I. scapularis ticks on Days 5, 12, 26, 40, 54, 68, 82, and 88. Efficacy was assessed at 48 h after each infestation. There were no adverse reactions to any treatment during the study. The placebo-treated cats maintained adequate tick infestations throughout the study. Three monthly treatments with selamectin plus sarolaner (Revolution® Plus) resulted in high and consistent efficacy against I. scapularis for up to 30 days after each treatment. Based on geometric means, efficacy was ≥99.1% at all time points assessed. Treatment with fluralaner (Bravecto® for Cats) provided high and consistent efficacy of ≥99.3% up to Day 70. On Day 84, efficacy was 90.1%; however, cats from which ticks were recovered on Day 84 had received approximately 4%-12% less than the minimum dosage of 40 mg/kg fluralaner. Three consecutive monthly treatments with Revolution® Plus or a single treatment with Bravecto® for Cats provided >90% control of I. scapularis ticks over a 12-week time period.
Collapse
Affiliation(s)
- Adriano F Vatta
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
| | - David R Young
- Young Veterinary Research Services, 7243 East Avenue, Turlock, CA, 95380, USA
| | - Vickie L King
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA
| | - Melanie R Myers
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA
| |
Collapse
|
3
|
Vatta AF, Young DR, Everett WR, King VL, Cherni JA, von Reitzenstein M, Holzmer SJ, Chapin S, Rugg D. Efficacy of a new topical formulation containing selamectin plus sarolaner against three common tick species infesting cats in the United States. Vet Parasitol 2019; 270 Suppl 1:S19-S25. [DOI: 10.1016/j.vetpar.2018.10.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 10/17/2018] [Accepted: 10/19/2018] [Indexed: 10/27/2022]
|
4
|
McTier TL, Pullins A, Chapin S, Rugg J, von Reitzenstein M, McCall JW, King VL, Vatta AF. The efficacy of a novel topical formulation of selamectin plus sarolaner (Revolution® Plus/Stronghold® Plus) in preventing the development of Dirofilaria immitis in cats. Vet Parasitol 2019; 270:56-62. [DOI: 10.1016/j.vetpar.2018.10.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Revised: 10/04/2018] [Accepted: 10/13/2018] [Indexed: 11/28/2022]
|
5
|
Efficacy and safety of a combination of selamectin plus sarolaner for the treatment and prevention of flea infestations and the treatment of ear mites in cats presented as veterinary patients in the United States. Vet Parasitol 2019; 270 Suppl 1:S3-S11. [DOI: 10.1016/j.vetpar.2018.11.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Revised: 11/19/2018] [Accepted: 11/20/2018] [Indexed: 01/30/2023]
|
6
|
Vatta AF, Everett WR, Cherni JA, King VL, Rugg D. The speed of kill of a topical combination of selamectin plus sarolaner against induced infestations of Ixodes scapularis ticks on cats. Vet Parasitol 2019; 270 Suppl 1:S26-S30. [DOI: 10.1016/j.vetpar.2018.10.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 10/23/2018] [Accepted: 10/23/2018] [Indexed: 01/30/2023]
|
7
|
Efficacy of three consecutive monthly doses of a topical formulation of selamectin and sarolaner (Revolution ® Plus/Stronghold ® Plus) compared with a single dose of fluralaner (Bravecto ® for Cats) against induced infestations of Ctenocephalides felis on cats. Vet Parasitol 2019; 270 Suppl 1:S52-S57. [PMID: 31133494 DOI: 10.1016/j.vetpar.2019.05.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Revised: 05/14/2019] [Accepted: 05/15/2019] [Indexed: 11/21/2022]
Abstract
In a controlled laboratory study, the efficacy against fleas, Ctenocephalides felis, of a single treatment of fluralaner topical solution (Bravecto® for Cats, Merck) was compared with that of three consecutive monthly topical treatments with selamectin and sarolaner (Revolution® Plus, Zoetis). Twenty-four domestic short hair cats were ranked based on host suitability flea counts to form groups of three and were randomly assigned within group to one of three treatments. The first group received a topical treatment with (a) placebo (vehicle control for Revolution® Plus) on Days 0, 30, and 60, (b) 6 mg/kg selamectin and 1 mg/kg sarolaner on Days 0, 30, and 60, or (c) 40 mg/kg fluralaner on Day 0 and placebo (vehicle control for Revolution® Plus) on Days 30 and 60. Because doses were rounded off, the selamectin plus sarolaner-treated cats received effective dosages of 5.25-6.60 mg/kg selamectin and 0.88-1.10 mg/kg sarolaner, while the fluralaner-treated cats received dosages of 34.71-43.08 mg/kg fluralaner. All cats were infested with 100 (±5) fleas on Day -1 and at biweekly intervals after that, from Day 13 to Day 89. Flea comb counts were conducted 24 hours after treatment or after re-infestation. There were no adverse events related to treatment during the study. Except for a single cat from which 20 fleas were recovered on Day 90, all other placebo-treated cats had at least 48 fleas at each count, indicating adequacy of infestation of the controls. Based on geometric mean live flea counts, three consecutive monthly treatments with Revolution® Plus resulted in consistent and high efficacy of ≥98.6% compared with placebo throughout the study. A single treatment with Bravecto® for Cats provided consistent and high efficacy of ≥94.6% on all count days during a period of 12 weeks, the approved duration of efficacy for the product. Based on the efficacy results of the study, both products were equivalent in their ability to control fleas on cats. Use of Bravecto® for Cats every 12 weeks or the consecutive monthly use of Revolution® Plus is expected to provide extended high residual kill over the respective labeled durations of efficacy of the two products.
Collapse
|
8
|
Yonetake W, Fujii T, Naito M, Hodge A, Maeder S, Rugg D. Efficacy of a new topical formulation of selamectin plus sarolaner for the control of fleas and ticks infesting cats in Japan. Vet Parasitol 2019; 270 Suppl 1:S12-S18. [PMID: 30914264 DOI: 10.1016/j.vetpar.2019.01.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Revised: 01/29/2019] [Accepted: 01/29/2019] [Indexed: 11/26/2022]
Abstract
The efficacy of a single application of a new topical formulation containing selamectin plus sarolaner (Revolution® Plus / Stronghold® Plus, Zoetis) was evaluated against fleas and ticks infesting cats enrolled as veterinary patients in two field studies conducted in Japan and against Haemaphysalis longicornis ticks on cats in a laboratory study. In the laboratory study, sixteen cats were ranked based on pre-treatment tick counts and allocated randomly to treatment on Day 0 with either selamectin plus sarolaner or placebo. Cats were infested with adult H. longicornis on Days -2, 5, 12, 19, 26 and 33. Efficacy relative to placebo was based on live attached tick counts conducted 48 h after treatment and subsequent re-infestations. Selamectin plus sarolaner reduced live, attached H. longicornis counts by 96.4% within 48 h of treatment, and by ≥91.7% within 48 h of weekly re-infestation for 35 days, based on arithmetic means. In the field studies, 67 client-owned cats harboring six or more live fleas and 63 cats harboring four or more live attached ticks were enrolled to evaluate selamectin plus sarolaner for efficacy and safety compared with a registered product. Cats were allocated randomly to treatment with selamectin plus sarolaner or fipronil plus (S)-methoprene based on order of presentation. Treatment was administered once on Day 0 and efficacy was assessed by parasite counts conducted on Days 14 and 30 compared to the pre-treatment count. In the flea field study, live flea counts on Days 14 and 30 were reduced by 99.5% and 99.9% in the selamectin plus sarolaner group, and by 97.6% and 98.6% in the fipronil plus (S)-methoprene group, based on least squares mean percentage reductions. Clinical signs typically associated with flea allergy dermatitis improved following treatment. In the tick field study, live tick counts on Days 14 and 30 were reduced by 97.5% and 97.7% in the selamectin plus sarolaner group, and by 91.5% and 93.4% in the fipronil plus (S)-methoprene group, based on least squares mean percentage reductions. Selamectin plus sarolaner was determined to be non-inferior to fipronil plus (S)-methoprene in both field studies. There were no treatment-related adverse events in any study. A single topical dose of Revolution® Plus / Stronghold® Plus providing a minimum dosage of 6.0 mg/kg selamectin and 1.0 mg/kg sarolaner was confirmed to be effective against H. longicornis ticks on cats for one month and safe and effective in the treatment of fleas and ticks on cats enrolled as veterinary patients in Japan.
Collapse
Affiliation(s)
- Wakako Yonetake
- Zoetis Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151-0053, Japan.
| | - Takeshi Fujii
- Zoetis Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151-0053, Japan
| | - Masaya Naito
- Shokukanken Inc., 561-21 Arakuchi-machi, Maebashi-shi, Gunma, Japan
| | - Andrew Hodge
- Zoetis Australia Research and Manufacturing, 5 Rider Boulevard, Rhodes, NSW, 2138, Australia
| | - Steven Maeder
- Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI, 49007, USA
| | - Douglas Rugg
- Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI, 49007, USA
| |
Collapse
|
9
|
Efficacy of a topical formulation of selamectin plus sarolaner against induced infestations of Amblyomma americanum on cats and prevention of Cytauxzoon felis transmission. Vet Parasitol 2018; 270 Suppl 1:S31-S37. [PMID: 30466895 DOI: 10.1016/j.vetpar.2018.10.018] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 10/26/2018] [Accepted: 10/28/2018] [Indexed: 11/18/2022]
Abstract
Cytauxzoonosis, caused by infection with Cytauxzoon felis, is the most severe tick-borne disease of cats. The purpose of our study was to determine the efficacy of selamectin (6.0 mg/kg) plus sarolaner (1.0 mg/kg) formulated in combination (Revolution® Plus / Stronghold® Plus, Zoetis) applied topically once a month on cats for three months against induced infestations of Amblyomma americanum adults and to evaluate the effectiveness of the product in preventing the transmission of C. felis. This study was conducted in two phases. Sixteen cats were dosed with selamectin/sarolaner or a placebo (vehicle control) on Days 0, 28, and 56. In phase 1, each cat was infested with 50 (±5) unfed adult A. americanum on Day 4 and tick counts were conducted on Day 6 (48 h post infestation) and Day 7 (72 h post infestation) to evaluate acaricidal efficacy. In phase 2, to confirm acaricidal efficacy and evaluate prevention of C. felis transmission, each cat was infested on Day 60 with 50 (±5) adult A. americanum acquisition fed as nymphs on two C. felis-infected donor cats. Tick counts were conducted on Day 62 (48 h post infestation) and Day 63 (72 h post infestation). Blood samples were collected on Days -9, 60, 70, 76, and 90 and tested for infection with C. felis. Placebo cats were adequately infested on all count days, with least squares (geometric) mean live tick counts ranging from 34.0 (28.8) to 46.1 (46.0). Treatment reduced the least squares (geometric) mean counts compared to placebo by 27.1 (32.1)% and 90.4 (96.8)% on Days 6 and 7, respectively. The corresponding percent reductions were 56.4 (60.6)% and 94.7 (97.3)% on Days 62 and 63, respectively. Least squares mean counts were significantly lower in the treated group compared with the placebo group on all count days (P ≤ 0.0286). All cats were negative for C. felis by PCR prior to study start. In phase 2, seven cats in the control group and no cats in the selamectin/sarolaner group became infected with C. felis (P = 0.0017). Topical treatment with selamectin/sarolaner was >90% effective in reducing A. americanum tick counts 72 h after infestation and prevented the transmission of C. felis from infected ticks following the third of three monthly treatments. Revolution® Plus / Stronghold® Plus offers an option for the control of A. americanum infestations on cats and for preventing the transmission of C. felis to cats.
Collapse
|
10
|
Vatta AF, Myers MR, Bowman DD, Rugg JJ, Damrah L, Therrien C, Liotta JL, Lucio-Forster A, King VL, Rugg D. Efficacy and safety of a new topical formulation of selamectin plus sarolaner in the treatment and control of natural infections of Ancylostoma tubaeforme and Toxocara cati in cats presented as veterinary patients in the United States. Vet Parasitol 2018; 270 Suppl 1:S45-S51. [PMID: 30470638 DOI: 10.1016/j.vetpar.2018.10.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Revised: 10/15/2018] [Accepted: 10/16/2018] [Indexed: 01/16/2023]
Abstract
A new topical formulation of selamectin plus sarolaner (Revolution® Plus/Stronghold® Plus, Zoetis) was evaluated in the treatment and control of naturally occurring infections of Ancylostoma tubaeforme and Toxocara cati in cats presented as veterinary patients in the United States. Three thousand three hundred three (3303) cats were screened in 25 veterinary practices in 15 states and 153 hookworm-positive cats (A. tubaeforme and/or A. braziliense), mainly from Alabama, Mississippi, Texas, and Hawaii, were identified; 135 cats met all the criteria for enrollment and were included on study. The cats were randomly assigned to treatment with Revolution® (at the label dosage, to provide a minimum dosage of 6 mg/kg selamectin) or selamectin plus sarolaner (at a dosage of 6-12 mg/kg plus 1-2 mg/kg, respectively). Treatments were administered at the time of enrollment and repeated 30 days later. Fecal samples were collected for differential fecal egg count prior to the first treatment (Day 0), prior to the second treatment (Day 30), and approximately 30 days later (Day 60). Efficacy was based on the percentage reductions in geometric mean fecal egg count for A. tubaeforme on Day 30 and Day 60 compared with Day 0. Where cats were co-infected with T. cati, efficacy against this species was also evaluated. Efficacy data were evaluated for A. tubaeforme for 40 cats on both Day 30 and Day 60 for the group treated with the selamectin/sarolaner combination and reductions in geometric mean fecal egg counts of 99.4% and 99.7% were demonstrated for Day 30 and Day 60, respectively. For the group treated with selamectin alone, 44 and 40 cats were evaluated and percent reductions for Day 30 and Day 60 were 99.5% and 99.9%, respectively. For T. cati, 14 cats were evaluated in the selamectin/sarolaner-treated group for Day 30 and for Day 60, and the reduction in geometric mean fecal egg count was 100% for both days. There were 11 and 9 cats evaluated for Day 30 and Day 60, respectively, for the selamectin-treated group and the reduction was again 100% for both days. The geometric mean fecal egg counts post-treatment were significantly lower than pre-treatment for both A. tubaeforme and T. cati, for both treatments, and for both periods of interest (P < 0.0001). No serious adverse events related to treatment with either product occurred during the study. Thus, both selamectin alone and the combination product of selamectin/sarolaner were safe and effective when administered on a monthly basis for the treatment and control of natural infections of A. tubaeforme and T. cati. The addition of sarolaner to the formulation did not interfere with the efficacy of selamectin against these nematodes.
Collapse
Affiliation(s)
- Adriano F Vatta
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
| | - Melanie R Myers
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA
| | - Dwight D Bowman
- Cornell University, Department of Microbiology and Immunology, College of Veterinary Medicine, 930 Campus Road, Ithaca, NY, 14853, USA
| | - Jady J Rugg
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA
| | - Lina Damrah
- The Veterinary Consultancy, LLC, 110 Summit Avenue, Montvale, NJ, 07645, USA
| | - Carole Therrien
- The Veterinary Consultancy, LLC, 110 Summit Avenue, Montvale, NJ, 07645, USA
| | - Janice L Liotta
- Cornell University, Department of Microbiology and Immunology, College of Veterinary Medicine, 930 Campus Road, Ithaca, NY, 14853, USA
| | - Araceli Lucio-Forster
- Cornell University, Department of Microbiology and Immunology, College of Veterinary Medicine, 930 Campus Road, Ithaca, NY, 14853, USA
| | - Vickie L King
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA
| | - Douglas Rugg
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA
| |
Collapse
|
11
|
Oliveira AC, Luz MF, Granada S, Vilhena H, Nachum-Biala Y, Lopes AP, Cardoso L, Baneth G. Molecular detection of Anaplasma bovis, Ehrlichia canis and Hepatozoon felis in cats from Luanda, Angola. Parasit Vectors 2018; 11:167. [PMID: 29554946 PMCID: PMC5859530 DOI: 10.1186/s13071-018-2767-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Accepted: 03/04/2018] [Indexed: 01/18/2023] Open
Abstract
Background Molecular identification of tick-borne pathogen infection in cats from Africa is scarce. The presence of bacterial (Anaplasma and Ehrlichia) and protozoal (Babesia and Hepatozoon) agents was investigated in blood samples from 102 domestic cats from Luanda, Angola, by polymerase chain reaction and DNA sequencing. Results Three cats (2.9%) were found infected with Ehrlichia canis, three (2.9%) with Hepatozoon felis and one (1.0%) with Anaplasma bovis. The prevalence of infections with one single agent was 4.9%, and that of infection with two agents (i.e. E. canis and H. felis) was 1.0%. In total, six cats (5.9%) were found infected with at least one of the detected tick-borne agents. Conclusions This is the first report of A. bovis, E. canis and H. felis in cats from Angola. To the best of our knowledge, A. bovis is also being reported for the first time in domestic cats outside of Japan. Cats are at a low to moderate risk of being infected with tick-borne agents in Luanda. Electronic supplementary material The online version of this article (10.1186/s13071-018-2767-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | | | | | - Hugo Vilhena
- Center for Investigation Vasco da Gama (CIVG), Department of Veterinary Medicine, Vasco da Gama University School, Coimbra, Portugal.,Baixo Vouga Veterinary Hospital, Águeda, Portugal.,Animal and Veterinary Research Centre (CECAV), University of Trás-os-Montes e Alto Douro (UTAD), Vila Real, Portugal
| | - Yaarit Nachum-Biala
- Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel
| | - Ana Patrícia Lopes
- Animal and Veterinary Research Centre (CECAV), University of Trás-os-Montes e Alto Douro (UTAD), Vila Real, Portugal.,Department of Veterinary Sciences, School of Agrarian and Veterinary Sciences (ECAV), UTAD, Vila Real, Portugal
| | - Luís Cardoso
- Animal and Veterinary Research Centre (CECAV), University of Trás-os-Montes e Alto Douro (UTAD), Vila Real, Portugal.,Department of Veterinary Sciences, School of Agrarian and Veterinary Sciences (ECAV), UTAD, Vila Real, Portugal
| | - Gad Baneth
- Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel.
| |
Collapse
|
12
|
Arthropod-borne pathogens of dogs and cats: From pathways and times of transmission to disease control. Vet Parasitol 2017; 251:68-77. [PMID: 29426479 DOI: 10.1016/j.vetpar.2017.12.021] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2017] [Revised: 12/25/2017] [Accepted: 12/26/2017] [Indexed: 11/21/2022]
Abstract
Vector-borne pathogens have developed a close relationship with blood feeding arthropod ectoparasites (e.g., mosquitoes, ticks, phlebotomine sand flies, black flies, fleas, kissing bugs, lice) and exploited a huge variety of vector transmission routes. Therefore, the life cycles of these pathogens result in a long evolved balance with the respective arthropod biology, ecology and blood feeding habits, instrumentally to the infection of several animal species, including humans. Amongst the many parasite transmission modes, such as ingestion of the arthropod, with its faeces or secretions, blood feeding represents the main focus for this article, as it is a central event to the life of almost all arthropod vectors. The time frame in which pathogens are transmitted to any animal host is governed by a large number of biological variables related to the vector, the pathogen, the host and environmental factors. Scientific data available on transmission times for each pathogen are discussed relative to their impact for the success of vector-borne disease control strategies. Blocking pathogen transmission, and thus preventing the infection of dogs and cats, may be achievable by the use of chemical compounds if they are characterised by a fast onset of killing activity or repellence against arthropods. The fast speed of kill exerted by systemic isoxazoline, as well as the repellent effect of pyrethroids have renewed the interest of the scientific community and pharmaceutical companies towards reducing the burden of vector-borne diseases under field conditions. However, endosymbionts and vaccines targeting arthropods or pathogen antigens should be further investigated as alternative strategies towards the goal of achieving an effective integrated control of vector-borne diseases.
Collapse
|
13
|
Otranto D, Dantas-Torres F, Napoli E, Solari Basano F, Deuster K, Pollmeier M, Capelli G, Brianti E. Season-long control of flea and tick infestations in a population of cats in the Aeolian archipelago using a collar containing 10% imidacloprid and 4.5% flumethrin. Vet Parasitol 2017; 248:80-83. [DOI: 10.1016/j.vetpar.2017.10.023] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Revised: 10/20/2017] [Accepted: 10/30/2017] [Indexed: 12/14/2022]
|
14
|
Geurden T, Borowski S, Wozniakiewicz M, King V, Fourie J, Liebenberg J. Comparative efficacy of a new spot-on combination product containing selamectin and sarolaner (Stronghold®Plus) versus fluralaner (Bravecto®) against induced infestations with Ixodes ricinus ticks on cats. Parasit Vectors 2017; 10:319. [PMID: 28662690 PMCID: PMC5492925 DOI: 10.1186/s13071-017-2259-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Accepted: 06/22/2017] [Indexed: 11/20/2022] Open
Abstract
Background Ticks are increasingly reported on cats worldwide, with Ixodes ricinus being a relevant species across Europe and in near by areas of North Africa and the Middle East. Yet there are few acaracidal products with proven efficacy approved for use in cats. The objective of this study was to compare the efficacy of a new spot-on formulation containing selamectin and sarolaner with a topical application of fluralaner (Bravecto®) against Ixodes ricinus ticks on cats. To that end, twenty-four (24) cats were randomly allocated to one of three treatment groups. The cats in the control group remained untreated. Cats in group 2 were treated with selamectin/sarolaner (Stronghold®Plus; Zoetis) at the minimum recommended dose of 1.0 mg/kg sarolaner and 6.0 mg/kg selamectin on Days 0, 30 and 60. The cats in group 3 received a fluralaner treatment (Bravecto®spot-on solution for cats, MSD) at the minimum recommended dose of 40.0 mg/kg on Day 0. Cats were infested with 50 (± 4) viable, adult, unfed I. ricinus ticks on Days 26, 54, 82 and 89 and ticks were removed for counting 48 h (± 2 h) later. Results Three monthly treatments with selamectin/sarolaner provided high and consistent efficacy against I. ricinus for the entire duration of the study period. In contrast, the efficacy of fluralaner declined in the second month after treatment and was below the efficacy threshold of 90% on Days 56, 84 and 91. The percentage efficacy against I. ricinus was numerically higher in the selemectin/sarolaner treated group than in the fluralaner-treated group on Days 56, 84 and 91. Furthermore, greasiness and spiking of the hair, as well as white deposits were frequently observed in the fluralaner-treated cats. Conclusion The results of the present study confirm the high and consistent efficacy of a new spot-on combination product containing selamectin and sarolaner against I. ricinus in cats, and indicate a decline in fluralaner efficacy during the 91 day period after treatment.
Collapse
Affiliation(s)
- Thomas Geurden
- Zoetis, Veterinary Medicine Research & Development, Mercuriusstraat 20, 1930, Zaventem, Belgium.
| | - Stasia Borowski
- Zoetis, Veterinary Medicine Research & Development, Mercuriusstraat 20, 1930, Zaventem, Belgium
| | - Magda Wozniakiewicz
- Zoetis, Veterinary Medicine Research & Development, Mercuriusstraat 20, 1930, Zaventem, Belgium
| | - Vickie King
- Zoetis, Veterinary Medicine Research & Development, Portage Road 333, Kalamazoo, MI, 49007, USA
| | - Josephus Fourie
- Clinvet, PO Box 11186, Universitas Bloemfontein, 9321, South Africa
| | | |
Collapse
|
15
|
Geurden T, Vatta AF, Slootmans N, King VL, Lin D, McTier T, Rugg D. Efficacy of a new spot-on formulation of selamectin plus sarolaner against Ancylostoma tubaeforme and Toxocara cati in cats. Vet Parasitol 2017; 238 Suppl 1:S31-S35. [DOI: 10.1016/j.vetpar.2017.02.027] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 01/30/2017] [Accepted: 02/23/2017] [Indexed: 10/19/2022]
|
16
|
Geurden T, Becskei C, Farkas R, Lin D, Rugg D. Efficacy and safety of a new spot-on formulation of selamectin plus sarolaner in the treatment of naturally occurring flea and tick infestations in cats presented as veterinary patients in Europe. Vet Parasitol 2017; 238 Suppl 1:S12-S17. [DOI: 10.1016/j.vetpar.2017.03.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 03/04/2017] [Accepted: 03/08/2017] [Indexed: 10/19/2022]
|
17
|
Becskei C, Lin D, Rugg D, Geurden T. Speed of kill of a new spot-on formulation of selamectin plus sarolaner for cats against induced infestations with Ixodes ricinus. Vet Parasitol 2017; 238 Suppl 1:S8-S11. [DOI: 10.1016/j.vetpar.2017.03.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 03/07/2017] [Accepted: 03/08/2017] [Indexed: 11/16/2022]
|